CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors

Recruiting now

Conditions studied: Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus

In brief

The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 \> 20%). The objective of this retrospective single-centre translational study will be to explore whether patients differ clinically in terms of diagnosis and treatment management. Currently, well differentiated high grade pulmonary NETs are managed using extrapolated algorithms from duodeno-pancreatic NETs, underlining a significant unmet clinical need. This is likely due to the rarity, uncertain pathological and molecular classification, and heterogeneous clinical course of well differentiated high grade pulmonary NETs. In this study a retrospective data-base of pulmonary, thymic and duodeno-pancreatic NETs with Ki-67 \> 20% will be created in order to analyze diagnostic and therapeutic pathways, clinical outcomes, imaging, disease evolution and molecular profiling. This study will adopt a hypothesis-generating approach to explore whether patients in these distinct groups differ clinically in terms of diagnosis and treatment management.

Key facts

Study ID

NCT07429851

Run by

European Institute of Oncology

People needed

34

Starts

2026-01-01

Expected to finish

2026-03-31

Last updated by the study team

2026-02-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 > 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist.
• Primary tumor site:thyme, lung and duodenum-pancreas NETs.
• Advanced stage of tumor disease and Any number of lines of therapy
• Sufficient available clinical data on diagnosis, treatments, outcomes.

You may not qualify if…

• Poorly differentiated neuroendocrine carcinomas (NECs), GEP NET G1/G2, pulmonary carcinoid with Ki-67 < 20%.
• Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs)
• Inadequate or unavailable tumor tissue for molecular analysis.
• Incomplete clinical records or follow-up.
• Other primary sites, except lung or pancreas.

Where it is running

• European Institute of Oncology — Milan, Italy, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.